Stock Analysis
Zenas BioPharma, Inc. (ZBIO) Stock Analysis
Zenas BioPharma, Inc. (ZBIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Zenas BioPharma, Inc. (ZBIO) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 78/100. Quality is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ZBIO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $28.01 |
| AIQ Score | 47/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $1.85B |
| P/E Ratio (TTM) | -2.79 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.65 |
| Revenue (Q3 FY2026) | $10M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.75 |
| Volume | 304.83K |
| 52-week range | $13.50-$44.60 |
| RSI 14 | 50.08 |
| 50-Day SMA | $28.58 |
| 200-Day SMA | $25.34 |
| Analyst Price Target | $55.00 |
| Next Earnings | Mar 15, 2027 |
ZBIOZenas BioPharma, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum78
- Value33
- Quality25
- Risk resilience39
- Sentiment—
ZBIO Stock Analysis Summary
Zenas BioPharma, Inc. (ZBIO) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 78/100. Quality is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, ZBIO has AIQ Score of 47/100 with Momentum base of 78/100 and fading Quality at 25/100. Wait for component alignment before adding exposure.
Momentum (78/100) leads while Quality (25/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.34% stock move · ZBIO classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ZBIO Bullish or Bearish Right Now?
ZBIO currently has a bearish overall setup. Momentum is the strongest factor at 78/100, while Quality is weakest at 25/100. The current evidence suggests a bearish setup.
- - Momentum is constructive at 78/100.
- - Analyst target implies +96.36% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (18 vs 13).
- - Value is the current constraint at 33/100.
- - Risk Resilience is weak at 39/100.
Current Consensus
ZBIO's Technical Analysis Consensus is currently Neutral, with 18 buy, 15 neutral, and 13 sell votes. ZBIO's 14-day RSI is 50.08, which places the stock in a neutral momentum range. ZBIO's beta is 0.75, indicating lower market sensitivity than the broad market.
What Changed in ZBIO?
The largest recent change in ZBIO is Momentum moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ZBIO Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ZBIO Decision Framework
Public evidence layers, setup checks, and risk context for Zenas BioPharma, Inc..
Zenas BioPharma, Inc. (ZBIO) Stock Analysis
Zenas BioPharma, Inc. has an AIQ Score of 47/100 in a Bearish regime. Momentum is strongest at 78/100. Beta is 0.75, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ZBIO is in a Bearish AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that momentum leads at 78/100 while quality lags at 25/100. |
| Factor Evidence | Momentum 78/100 · Value 33/100 · Quality 25/100 · Risk 39/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 78/100.
Momentum is 78/100 and RSI (14) is 50.1.
ZBIO is in a Bearish regime at 47/100.
Risk factor is 39/100 with beta 0.75 and annual volatility 95.33%.
Current conflict: momentum leads at 78/100 while quality lags at 25/100.
ZBIO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ZBIO Fundamentals
ZBIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ZBIO Technical Analysis
ZBIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ZBIO Stock Catalysts
Track ZBIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ZBIO Dividend Analysis
ZBIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ZBIO Financial Data
ZBIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ZBIO Risk Analysis
ZBIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ZBIO Stock News
ZBIO stock news, market tone, recent headlines, and catalyst context.
ZBIO vs Biotechnology Peers
Current peer cohort: ZBIO · ZYME · ABCL · ABSI · ABUS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ZBIO Current stock | 47/100 | 33/100 | 78/100 | 39/100 | 0.26 | 95.33% | Current |
| ZYME Zymeworks Inc. | 68/100 | 66/100 | 78/100 | 61/100 | 0.84 | 54.03% | ZBIO vs ZYME |
| ABCL AbCellera Biologics Inc. | 64/100 | 47/100 | 89/100 | 34/100 | 1.73 | 85.28% | ZBIO vs ABCL |
| ABSI Absci Corporation | 53/100 | — | 85/100 | 30/100 | 1.58 | 104.15% | ZBIO vs ABSI |
| ABUS Arbutus Biopharma Corp | 70/100 | 92/100 | 51/100 | 62/100 | -0.09 | 45.89% | ZBIO vs ABUS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ZBIO: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ZBIO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ZBIO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ZBIO Stock FAQ
What is ZBIO stock price today?
Zenas BioPharma, Inc.'s current stock price is $28.01. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ZBIO bullish or bearish right now?
ZBIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ZBIO's market cap?
ZBIO's market cap is $1.85B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ZBIO's current P/E ratio?
ZBIO's current P/E ratio is -2.79 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ZBIO's RSI?
ZBIO's 14-day RSI is 50.08 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ZBIO above its 50-day and 200-day moving averages?
ZBIO is -2.00% from its 50-day SMA and 10.53% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ZBIO's next earnings date?
ZBIO's next earnings date is currently listed as Mar 15, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ZBIO pay a dividend?
ZBIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.